ETIDIOH - NEW

  Antiviral Res HEDSKOG C, Rodriguez L, Hu Y, Li J, et al SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19. Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351. PubMed           Abstract available BMJ HIGGS J Help me piece my story together. BMJ. 2026;392:r2624. PubMed          RUSSELL MD, Schaffer A, Bechman K, Gibson M, et al Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY. BMJ. 2026;392:e086393. PubMed           Abstract available Clin Infect Dis WINOKUR P, Diya O, Fitz-Patrick D, Dever M, et al Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18?55 Years Old. Clin Infect Dis. 2026 Jan 21...

  Ann Intern Med SACKS HS In older adults, RSV prefusion F vaccine reduced hospitalization for RSV-related respiratory tract disease vs. no vaccine. Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-05113. PubMed           Abstract available SOUMARE A, Kapfer T, Botrel T, Adda L, et al Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis. Ann Intern Med. 2025 Dec 2. doi: 10.7326/ANNALS-25-03055. PubMed           Abstract available Arch Virol LAI QR, Chen W, Yu GF, Guo YJ, et al Molecular epidemiology and clinical characteristics of human adenovirus in children in Hangzhou (2022-2023). Arch Virol. 2026;171:60. PubMed           Abstract available Biochem Biophys Res Commun WU X, Bhatt V, Liu JJ, Hong L, et al Single-cell RNA sequencing data analysis reveals differential expr...

  Abstract The association between vaccine efficacy (VE) and force of infection (FoI) remains incompletely understood . Previous analyses have been primarily based on trial-level summary data—not accounting for the effect of time and constrained by the number of trials. Here, we leverage individual-level data from three phase 3 randomized, placebo-controlled COVID-19 vaccine trials —the COVE trial (Moderna, CoVPN3001), the AZD1222 trial (AstraZeneca, CoVPN3002), and the ENSEMBLE trial (Janssen/Johnson & Johnson, CoVPN3003)—and contemporaneous geographic-location-specific SARS-CoV-2 surveillance data from the start of the pandemic through November 14, 2021 (including the blinded follow-up periods of the trials) to conduct five cohort- and vaccine-specific analyses: COVE (U.S.), AZD1222 overall (U.S. + non-U.S.), AZD1222 U.S., ENSEMBLE overall (U.S. + non-U.S.), and ENSEMBLE U.S. In AZD1222 U.S., higher VE was associated with higher FoI (p = 0.01). In ENSEMBLE overall, lower VE w...

  BMJ MARTIN DS, Doidge JC, Gould D, Shahid T, et al The impact of skin tone on performance of pulse oximeters used by NHS England COVID Oximetry @home scheme: measurement and diagnostic accuracy study. BMJ. 2026;392:e085535. PubMed           Abstract available Int J Infect Dis AMODIO E, Aiello R, Battisti M, Casuccio A, et al Past Behavior Predicts Future Protection: Uncovering Key Drivers of Influenza Vaccine Acceptance in Italy in the Post-Pandemic Era. Int J Infect Dis. 2026 Jan 8:108379. doi: 10.1016/j.ijid.2026.108379. PubMed           Abstract available SEO G, Joo H, Song K, Kim M, et al Static and Dynamic Scoring Systems for Post-acute Sequelae of SARS-CoV-2 in a Korean Cohort. Int J Infect Dis. 2026 Jan 9:108378. doi: 10.1016/j.ijid.2026.108378. PubMed           Abstract available PIOVESAN C, Fabiani M, Pezzotti P, Ramigni M, et al Mortality for causes un...

  Antiviral Res LEEKHA A, Reichel K, Hurst B, Varadarajan N, et al Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains. Antiviral Res. 2026 Jan 14:106342. doi: 10.1016/j.antiviral.2026.106342. PubMed           Abstract available BMJ MARTIN DS, Doidge JC, Gould D, Shahid T, et al The impact of skin tone on performance of pulse oximeters used by NHS England COVID Oximetry @home scheme: measurement and diagnostic accuracy study. BMJ. 2026;392:e085535. PubMed           Abstract available Drug Saf PALMER M, Seekins D, Avigan M, Marcinak J, et al The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative. Drug Saf. 2026;49:9-25. PubMed        ...

  Abstract Previous studies have documented an increased risk for thrombotic events 30 days after COVID-19 infection , but less is known about this risk beyond 30 days or compared with risk after other infectious acute respiratory illnesses (ARIs). By using PCORnet data from April 1, 2022–April 30, 2023 , we compared the incidences of thrombotic events in the year after COVID-19 illness with other ARI diagnoses in hospitalized and nonhospitalized patients. Overall, the risk for any thrombotic event was higher among patients with COVID-19 compared with patients with other ARIs (incidence ratio 1.63; p<0.05). Nonhospitalized patients with COVID-19 had a 73% increased risk for a thrombotic event in the year after acute illness compared with nonhospitalized patients with ARI (p<0.05). The increased risk for thrombotic events in the year after COVID-19 emphasizes the need for stroke awareness for patients and healthcare professionals. Source:  Link:  https://wwwnc.cdc.go...

  {Excerpt} In the spring of 2025, multiple SARS-CoV-2 Omicron JN.1 subvariants were circulating, with LP.8.1 among the major variants . Pharmaceutical companies, such as Pfizer–BioNTech, Moderna, and Novavax–Takeda, adopted monovalent LP.8.1 for their 2025–26 season vaccines , following recommendations issued by WHO in May, 2025. As of November, 2025, SARS-CoV-2 variants including LP.8.1, XEC, NB.1.8.1, and XFG —all designated as variants under monitoring —were circulating. In terms of the spike gene , these variants, as well as LP.8.1, are derived from JN.1 . Moreover, BA.3.2, a BA.3 descendant bearing multiple mutations in its spike gene , has potentially been spreading and exhibiting robust immune evasion . In Japan, the roll-out of the LP.8.1-based vaccination has progressed since the end of September, 2025. We previously reported the humoral immunity induced by the XBB.1.5-based monovalent vaccine in 2023,6 and the JN.1-based monovalent vaccine in 2024 in the Japanese populat...

  BMJ FLINDERS M, Cairney P, Elliott IC Delivering change after the UK covid inquiry. BMJ. 2026;392:s18. PubMed          YAMEY G, Shaffer J Trump and RFK Jr are dismantling public health-aided and abetted by powerful doctors. BMJ. 2026;392:s19. PubMed          Clin Infect Dis RAO A, Johnson L, Bassit L, Sullivan J, et al Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2. Clin Infect Dis. 2026 Jan 9:ciaf660. doi: 10.1093. PubMed           Abstract available WANG XF, Calabrese C, Calabrese L Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients-Reply to Chen et al. Clin Infect Dis. 2026 Jan 9:ciaf718. doi: 10.1093. PubMed          PURPURA L, Heisler T, Palmer S, Shah J, et al Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vacc...

  Ann Intern Med TERAN-PLASENCIA JM, Kalil AC In adults hospitalized with acute HF, predischarge influenza vaccination reduced a composite of mortality or readmission at 1 y. Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-04799. PubMed           Abstract available TONG SYC, Gibney KB In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia. Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-05209. PubMed           Abstract available Arch Virol YAN Y, Pan Z, Mao L, Niu P, et al Genome surveillance of SARS-CoV-2 Omicron XBB subvariants in Wuhan in June 2023. Arch Virol. 2026;171:38. PubMed           Abstract available Biochem Biophys Res Commun HUANG A, Li C, Wu H, Sun W, et al Development of human single-domain antibodies against influenza based on NA-targeting IgG. Biochem Biophys Res Commun. 2026;798:153238...